Search | Clinical Trials Finder

Conditions: Depression, Ketosis
Interventions: Ketogenic Diet, NIH Toolbox, gradCPT, Resting-state fMRI, Task-fMRI, CGM/CKM, Blood Draw, Sleep Monitoring, Ketone/Glucose Monitoring, Body Composition, PHQ-9, WHO-5, SKID; Other · Biological · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Any Chronic, Non-traumatic Orthopedic Condition
Interventions: LLM-facilitated cognitive debiasing aid; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Immunology
Interventions: BMS-986020, [11C]BMT-136088; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 207
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more

Conditions: Opiate Overdose, Fentanyl Overdose, Harm Reduction
Interventions: Fentanyl Test Strips; Behavioral
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Pharmacogenetic testing; Genetic
Lead sponsor: Genelex Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Searcy, Arkansas

Conditions: Healthy Adult, Fitness Testing, Athlete, Aging, Exercise Physiology, Human Performance
Interventions: There is no intervention.; Other
Lead sponsor: VO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Motion Sickness, Vertigo, Dizziness, Fall
Interventions: sensory re-weighting; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 59 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myeloma
Interventions: Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up; Drug · Other
Lead sponsor: Robert Redner, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 22
States / cities: Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more

Conditions: Parkinson's Disease (PD), Essential Tremor
Interventions: Phoneme sequence learning, Cessation and re-enabling of stimulation of the STN, Cessation and re-enabling of stimulation of the VIM thalamic nucleus, Multisyllabic sequence learning; Behavioral · Other
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lower Limb Amputation Below Knee (Injury)
Interventions: Release/Relock Socket - In Lab, Release/Relock Socket - Out of Lab, Release/Relock Socket & Control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions: Iron isomaltoside/ferric derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Chula Vista, California • La Mesa, California • Northridge, California + 15 more

Conditions: Dizziness, Vertigo, Vestibular Migraine, Vestibular Neuritis, Labyrinthitis
Interventions: Otoband, Placebo Device; Device
Lead sponsor: Otolith Labs; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Smoking Cessation, Acceptability of Health Care, Nicotine Dependence, Cigarettes
Interventions: Abstinent Contingent (AC) Re-Connect, Submission Contingent (SC) Re-Connect; Behavioral
Lead sponsor: Rowan University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Glassboro, New Jersey

Conditions: Gastric Carcinoma
Interventions: Biopsy, Biospecimen Collection, Breath Test, Esophagogastroduodenoscopy, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Shock
Interventions: Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility, CURVES Questionnaire, Lactate Clearance, 500ml Normal Saline Bolus, Clinician Discretion Intravenous Fluid Management; Device · Behavioral · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cocaine-Related Disorders, HIV, Heroin Dependence
Interventions: Methadone, Buprenorphine, Employment-based drug abstinence reinforcement; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cystic Fibrosis
Interventions: Airway-clearance vest, Hyperpolarized Xe129; Procedure · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Venous Leg Ulcer
Interventions: TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Carlsbad, California • Sylmar, California • North Chicago, Illinois + 3 more

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 16 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Nashville, Tennessee • Charlottesville, Virginia • Richmond, Virginia + 1 more

Conditions: Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Headache, Visual Impairment
Interventions: Non-interventional study; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: San Diego, California • Newark, Delaware • Boca Raton, Florida + 19 more

Conditions: HIV Prevention Program, Pre-Exposure Prophylaxis (PrEP)
Interventions: Nurse-Led Intervention, Patient Navigation Intervention, Standard-of-care (SoC); Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Ketogenic Intervention in Depression

Testing an AI Large Language Model Tool for Cognitive Debiasing in Musculoskeletal Care

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants

Pharmacogenetic Testing Among Home Health Patients

Molecular Indicators of Systematic Fitness

Sensory Training for Orientation and Balance

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients

NIH Release/Relock Socket

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness

Re-Connect Application for Smoking Cessation

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)

Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Regional Monitoring of CF Lung Disease

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

Nurse-Led PrEP Initiation Among Incarcerated Individuals